MSF warns $28,000 annual cost limits access to Gilead's HIV prevention injection
GS2Polity · Governance · IR· Health policy & public health· Prelims + Mains·
Pharmaceutical pricing vs. global health equity: a GS2 case study on access to life-saving medicines.
Why in news
MSF warned that the $28,000 annual cost of Gilead's lenacapavir injection limits access to HIV prevention, despite its efficacy in clinical trials.
Background
Gilead Sciences developed lenacapavir, a twice-yearly injection for HIV prevention. A 2024 trial involving over 2,000 women in South Africa and Uganda showed zero infections.
Facts for Prelims
- S&TLenacapavir: A twice-yearly injection for HIV prevention developed by Gilead Sciences.
- FactFDA approved lenacapavir in June 2025.
- FactUNAIDS reported funding fell to $7.3bn in 2025.
- FactGilead plans to provide lenacapavir for 3 million people through 2028.
Prelims practice question
What is the reported amount of UNAIDS funding in 2025?
- (a)$10bn
- (b)$5bn
- (c)$7.3bn
- (d)$12bn
Show answer
Answer: (c) $7.3bn — The note states that UNAIDS reported funding fell to $7.3bn in 2025.
For Mains
Q. Discuss the challenges of balancing pharmaceutical innovation with equitable access to life-saving medicines in low-income countries.
Dimensions to cover in your answer
- Affordability gap: High annual costs of $28,000 creating barriers for public health systems in developing nations
- Funding shortfall: Declining UNAIDS funding to $7.3bn impacting large-scale HIV prevention initiatives
- Scale-up constraints: Limitations in Gilead's plan to reach 3 million people by 2028 due to cost
Keywords: Equitable access · Pharmaceutical pricing · Public health infrastructure · Global health equity · Preventive medicine
More Social Justice notes
- Kerala issues 10,000 title deeds for Attappady land to SC, ST and fishing communities · 8 October 2026
- Supreme Court directs Union government to form committee on legally enforceable pharmaceutical marketing code · 8 October 2026
- Finance Ministry mandates bank-wise data on SC beneficiaries for Mudra, Stand Up India schemes · 8 October 2026
- Madras High Court dismisses Kanzeon Trust appeal after it misrepresented Zen Buddhist activities · 8 October 2026
- Tamil Nadu amends Thaimaaman Thanga Mothiram Thittam to include children of out-of-state mothers · 8 October 2026
- Odisha forms Justice Pramath Patnaik-led commission to study SEBC representation before next year's polls · 8 October 2026
Something wrong, or something missing?
Spotted a mistake in a note, or want a topic, format or PDF that would help your preparation? Write to us. We read every mail and fix errors fast.
Report a mistake →Ask for something →thesatyadheesh@gmail.com
This note is generated automatically from SatyaDheesh's news feed and mapped to the UPSC CSE syllabus. Check facts against the original report or PIB before using them in an answer.